Cancer Advisor

Abstract Background Pancreatic cancer remains one of the most lethal malignancies despite modern chemotherapy. Increasing public interest has emerged around repurposed antiparasitic drugs such as fenbendazole, mebendazole, and ivermectin. Objective To reorganise and analyse anecdotal pancreatic cancer case reports involving fenbendazole and ivermectin-based protocols in order to identify recurring response patterns and clinically relevant subgroups. Methods Publicly available anecdotal reports were reviewed qualitatively and reorganised according to biomarker response, metastatic pattern, chemotherapy use, histology, and adjunct metabolic therapies. Results Recurring themes included rapid CA19-9 decline, apparent liver metastasis responses, heavy reliance on combination chemotherapy, delayed-response patterns, and extensive use of nutraceutical adjuncts. Most reported responders received multi-modal therapy rather than antiparasitic monotherapy. Conclusion The reports are highly vulner...

Daraxonrasib (RMC-6236) nearly doubles median survival in previously treated metastatic pancreatic cancer (13.2 vs. 6.7 months) with a 60% reduction in death risk. Learn about the breakthrough RAS(ON) inhibitor, side effects, trial results, cost concerns, and what it means for patients in 2026. Pancreatic cancer remains one of the deadliest cancers, with a 5-year survival rate under 13% overall and just 3% for metastatic disease. But in May 2026, a new oral pill called daraxonrasib (also known as RMC-6236) delivered what experts are calling “historic” and “practice-changing” results.In the pivotal Phase 3 RASolute 302 trial, daraxonrasib doubled median overall survival and cut the risk of death by 60% compared to standard chemotherapy — all while being better tolerated for many patients.  Here’s everything you need to know about this groundbreaking pancreatic cancer treatment, including the science, real-world implications, side effects, cost debates, and expert perspectives. What ...